Literature DB >> 17429046

Enzyme replacement therapy and Fabry kidney disease: quo vadis?

David G Warnock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429046     DOI: 10.1681/ASN.2007030312

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  2 in total

1.  Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.

Authors:  Gregory M Pastores
Journal:  Biologics       Date:  2007-09

2.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.